Charlie Harper
charlie-harper.bsky.social
Charlie Harper
@charlie-harper.bsky.social
Trial Data Scientist, CTSU, Oxford Population Health, University of Oxford, UK. Advocating for better use of NHS data for large streamlined randomized trials.
Reposted by Charlie Harper
It's no longer binary: normal or abnormal.
We've known that A.I. can predict future risk of breast cancer from a mammogram
jamanetwork.com/journals/jam...
Today the FDA approved an A.I. to do this for 5-year risk assessment
clairity.com @connielehman.bsky.social
June 2, 2025 at 6:35 PM
Reposted by Charlie Harper
It’s the hardest thing to balance within you the full acknowledgement of how unfair humans are to their fellow humans with the full trust that humanity can be the most powerful tool for justice.
May 17, 2025 at 8:01 AM
Reposted by Charlie Harper
Patients who experience a transient ischemic attack (TIA) or minor stroke face a high risk of subsequent strokes, emphasizing the need for both short-term and long-term prevention strategies.

ja.ma/4kA2xhh
May 12, 2025 at 1:37 PM
Reposted by Charlie Harper
New @nejm.org
Another win for semaglutide (Ozempic) and the GLP-1 drugs: reduction of liver fibrosis in MASH
www.nejm.org/doi/full/10....
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | NEJM
Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter, randomize...
www.nejm.org
April 30, 2025 at 10:05 PM
Reposted by Charlie Harper
PhD Student, Ella Howes, has just released the latest episode of the Trials Methodology podcast with our very own @willjcragg.bsky.social , covering all things to do with the 'how' of trials methodology💡

Give it a listen here (or on Apple podcasts if you prefer): open.spotify.com/episode/04JZ...
March 25, 2025 at 3:48 PM
Reposted by Charlie Harper
“Yes, I deserve a spring - I owe nobody nothing.”

Virginia Woolf
March 17, 2025 at 7:52 AM
Reposted by Charlie Harper
UK academia pretends to be a business by maximising threats and minimising incentives for its staff.

That’s not how successful businesses run.
February 26, 2025 at 7:20 PM
Reposted by Charlie Harper
The scientist who is responsible for driving GLP-1 drugs for the treatment of obesity and testing them for prevention of Alzheimer's disease—Lotte Bjerre Knudsen— tells her story in a remarkable conversation. Full transcript, or video, all free, no ads.
erictopol.substack.com/p/lotte-bjer...
Lotte Bjerre Knudsen: The Scientist Who Drove GLP-1 Drugs For Obesity and Alzheimer's
Facts, data, and analytics about biomedical matters.
erictopol.substack.com
January 4, 2025 at 6:30 PM
Reposted by Charlie Harper
December 12, 2024 at 4:53 PM
Reposted by Charlie Harper
Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart), by Chris Wilkinson et al academic.oup.com/eurheartj/ad...
November 25, 2024 at 11:08 AM
Reposted by Charlie Harper
Aspirin for *primary prevention* of cardiovascular disease has been shown to cause more bleeding than benefit in randomized trials over the past 5 years. But it's still being taken by 1 of 3 older Americans.
www.acpjournals.org/doi/abs/10.7...
June 24, 2024 at 10:30 PM
Reposted by Charlie Harper

Real-time Adaptive Randomization of Clinical Trials - Journal of Clinical Epidemiology www.jclinepi.com/article/S089...
November 22, 2024 at 8:26 AM
Reposted by Charlie Harper
Some superiority trials with non-significant results published in high impact factor journals correspond to non-inferiority situations: a research-on-research study - Journal of Clinical Epidemiology www.jclinepi.com/article/S089...
Some superiority trials with non-significant results published in high impact factor journals correspond to non-inferiority situations: a research-on-research study
Many negative randomized controlled trials (RCTs) report spin in their conclusions to highlight the benefits of the experimental arm, which could correspond to a non-inferiority (NI) objective. We aim...
www.jclinepi.com
November 22, 2024 at 8:15 PM
Reposted by Charlie Harper
A methodological review identified several options for utilizing registries for randomized controlled trials - Journal of Clinical Epidemiology www.jclinepi.com/article/S089...
November 23, 2024 at 1:36 AM
Reposted by Charlie Harper
Featured Science Sim Pub with #AHA24 from @PabloMikiMarti & @scottdsolomon et al published in #CircHF:
Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical Trials
#AHAJournals

Read more: https://ahajrnls.org/40Q1DpV
November 16, 2024 at 7:30 PM
Reposted by Charlie Harper
This is huge news.

This opens up the possibility of a viable treatment for a range of auto-inmune diseases, not just Lupus.

www.science.org/content/arti...
A breakthrough cancer immunotherapy is now taking aim at autoimmune disease
CAR-T therapy is generating excitement for lupus, scleroderma, and other conditions as clinical trials expand
www.science.org
November 16, 2024 at 12:16 AM
Reposted by Charlie Harper
Another GLP-1 drug success. Tirzepatide in heart failure with preserved ejection fraction (HFpEF) with longer term follow-up than 2 previous trials with semaglutide
nejm.org/doi/full/10....
in people with BMI >30; no data yet for HFpEF in people without obesity
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | NEJM
Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor...
nejm.org
November 16, 2024 at 3:12 PM
Reposted by Charlie Harper
To conclude our Pirates series, our newest Empire episode looks into the real history behind one of the most famous fictional pirates - Captain Hook.

Peter Pan is a story that has continued to inspire generations, but the truth behind its creation is wrapped up in tragedy and darkness...

🧚🏴‍☠️🧚🏴‍☠️🧚🏴‍☠️🧚🏴‍☠️
November 14, 2024 at 11:11 AM
Reposted by Charlie Harper
A large randomized trial in people with Type 2 diabetes showed intensive BP lowering (systolic < 120 mm Hg) reduced major cardiovascular outcomes
www.nejm.org/doi/full/10....
November 16, 2024 at 2:46 PM